TRIBE2 results and toxicity – Authors' reply
Volume: 21, Issue: 6, Pages: e300 - e301
Published: Jun 1, 2020
Abstract
We thank Jianwei Zhang and colleagues for their considerations. Regarding patients with BRAF-mutated tumours, both in TRIBE 1 Cremolini C Loupakis F Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16: 1306-1315 Summary Full Text...
Paper Details
Title
TRIBE2 results and toxicity – Authors' reply
Published Date
Jun 1, 2020
Volume
21
Issue
6
Pages
e300 - e301
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History